Eisai (ESALY) News Today $61.51 -1.33 (-2.11%) As of 01/30/2023 Add Compare Share Share Headlines Stock AnalysisBuy This Stock ESALY Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Eisai Begins Rolling SBLA Submission For LEQEMBI IQLIK Subcutaneous AutoinjectorSeptember 3, 2025 | finanznachrichten.deEcoNaviSta, Inc. Supports Eisai Co., Ltd.’s Tender OfferMarch 14, 2025 | tipranks.comEisai stock price target cut to JPY5,000 at Citi, retains Buy ratingFebruary 10, 2025 | msn.comEli Lilly's Alzheimer's Drug Raises Hopes but Faces Regulatory Hurdles in EuropeOctober 14, 2024 | finance.yahoo.comAlzheimer's drug Leqembi promises to give patients more time, but they face a long road to treatmentSeptember 8, 2024 | cnbc.comThis matcha set helped me break my coffee addiction and I’ve never looked backSeptember 2, 2024 | msn.comEisai Co., Ltd. (ESAIY)July 27, 2024 | finance.yahoo.comBiogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side EventsJuly 26, 2024 | msn.comEisai Co. Ltd. ADRMarch 29, 2024 | wsj.comEisai Co LtdMarch 23, 2024 | reuters.comEisai Co Ltd 4523March 20, 2024 | morningstar.comMBIIB Mar 2024 210.000 callFebruary 15, 2024 | finance.yahoo.comBIIB Feb 2024 227.500 callFebruary 15, 2024 | finance.yahoo.comBIIB Mar 2024 235.000 callFebruary 15, 2024 | finance.yahoo.comBIIB Mar 2024 205.000 putFebruary 14, 2024 | finance.yahoo.comESALF Eisai Co., Ltd.January 12, 2024 | seekingalpha.comMerck Says Phase 3 LEAP-001 Trial Evaluating KEYTRUDA Plus LENVIMA Did Not Meet EndpointsDecember 8, 2023 | markets.businessinsider.comJapan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment LeqembiSeptember 25, 2023 | msn.comMerck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung CancerSeptember 22, 2023 | msn.comBiogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi (ESALY)Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.July 10, 2023 | marketbeat.comFDA Grants Traditional Approval To Eisai's Leqembi To Treat Adult Patients With Alzheimer's DiseaseJuly 6, 2023 | markets.businessinsider.comAlzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare ResourcesJune 13, 2023 | benzinga.comFDA Panel Recommends Full Approval For Biogen And Eisai's Alzheimer's Drug LeqembiJune 11, 2023 | markets.businessinsider.comBernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'June 8, 2023 | msn.comUTHR or ESALY: Which Is the Better Value Stock Right Now?January 9, 2023 | finance.yahoo.comFDA approves treatment for people with mild forms of Alzheimer’sJanuary 6, 2023 | finance.yahoo.comDespite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's CandidateNovember 30, 2022 | finance.yahoo.comBiogen rallies Alzheimer’s drug developers after full data for lecanemabNovember 30, 2022 | seekingalpha.comOpen Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer'sNovember 30, 2022 | finance.yahoo.comBiogen's lecanemab shows less cognitive decline with Alzheimer's, but more brain swellingNovember 30, 2022 | seekingalpha.comBiogen and Eisai’s Alzheimer’s Data Confirm Benefit. Questions Still Loom.November 30, 2022 | barrons.comBiogen drops after report on second death linked to Alzheimer’s candidateNovember 28, 2022 | seekingalpha.comUTHR vs. ESALY: Which Stock Is the Better Value Option?November 28, 2022 | finance.yahoo.comAfter Rallying 50% in the Last 2 Months, Is Biogen Stock Still a Buy?November 17, 2022 | msn.comRoche's Alzheimer's Flop Trial Removes One Competitor, But Reimbursement Debate LingersNovember 15, 2022 | finance.yahoo.comFY2024 Earnings Estimate for Eisai Co., Ltd. (OTCMKTS:ESALY) Issued By Jefferies Financial GroupNovember 2, 2022 | marketbeat.comPatient Death in Alzheimer's Study May Limit Drug's ReachOctober 29, 2022 | msn.comBiogen Alzheimer’s data de-risked beta amyloid hypothesis - Roche executiveOctober 18, 2022 | seekingalpha.comDespite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say ResearchersOctober 18, 2022 | finance.yahoo.comBiogen shares soar on landmark Alzheimer's data, lift rivalsSeptember 29, 2022 | investing.comMany Alzheimer's drug developers close significantly higher thanks to Biogen, Eisai dataSeptember 28, 2022 | seekingalpha.comThis Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS ApprovalSeptember 28, 2022 | finance.yahoo.com2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug DataSeptember 28, 2022 | markets.businessinsider.comAnalysis-Alzheimer's drug breakthrough big boost for Roche, Eli LillySeptember 28, 2022 | investing.comBiogen, Eisai drive rally in Alzheimer’s stocks as lecanemab succeeds in late-stage trialSeptember 28, 2022 | seekingalpha.comBiogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks GameSeptember 28, 2022 | realmoney.thestreet.comIs This the First Alzheimer's Drug to Actually Work?September 28, 2022 | msn.comEisai says Alzheimer's drug succeeds in slowing cognitive declineSeptember 28, 2022 | investing.comBiogen, Eisai Alzheimer's candidate lecanemab meets primary endpoint in late-stage trialSeptember 28, 2022 | seekingalpha.comPharmaceutical Makers Eisai and Biogen Claim Success in Latest Alzheimer’s Drug TrialSeptember 27, 2022 | barrons.com Get Eisai News Delivered to You Automatically Sign up to receive the latest news and ratings for ESALY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESALY Media Mentions By Week ESALY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ESALY News Sentiment▼0.000.84▲Average Medical News Sentiment ESALY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ESALY Articles This Week▼10▲ESALY Articles Average Week Get the Latest News and Ratings for ESALY and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Eisai and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CMPGY News Today BAMXF News Today JAPAY News Today SGAPY News Today DHLGY News Today BMWYY News Today SSREY News Today MIELF News Today BHKLY News Today MIELY News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:ESALY) was last updated on 9/10/2025 by MarketBeat.com Staff From Our PartnersWall Street Legend Issues Urgent AI Stock WarningChaikin's stepping forward with a new warning – focused on the red-hot A.I. frenzy taking the U.S. stock marke...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eisai Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eisai With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESALY Stock Alerts